Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A David Rodrigues

Showing results (121-130 of 132) with videos related to

Pageof 14
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 27, 2015
Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo EvaluationHong Shen, Tongtong Liu, Hao Jiang, et al.
Pharmaceutical Research|August 10, 2023
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter ActivityYeamin Huh, Anna Plotka, Hua Wei, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 3, 2006
Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteersStacey L Polsky-Fisher, Stanley Vickers, Donghui Cui, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2019
Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: "SLC-Phenotyping" Using Primary Human HepatocytesYi-An Bi, Chester Costales, Sumathy Mathialagan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2017
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting PolypeptidesRhishikesh Thakare, Hongying Gao, Rachel E Kosa, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2015
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699Zheng Yang, Haiqing Wang, Theodora W Salcedo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Pageof 14

Showing results (121-130 of 132) with videos related to

Sort By:
Pageof 14
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 27, 2015
Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo EvaluationHong Shen, Tongtong Liu, Hao Jiang, et al.
Pharmaceutical Research|August 10, 2023
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter ActivityYeamin Huh, Anna Plotka, Hua Wei, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 3, 2006
Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteersStacey L Polsky-Fisher, Stanley Vickers, Donghui Cui, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|July 2, 2022
<b>Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, A First-in-class Ketohexokinase Inhibitor for Metabolic Disorders and Non-alcoholic Fatty Liver Disease</b>Yan Weng, Kari R Fonseca, Yi-An Bi, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 13, 2019
Quantitative Contribution of Six Major Transporters to the Hepatic Uptake of Drugs: "SLC-Phenotyping" Using Primary Human HepatocytesYi-An Bi, Chester Costales, Sumathy Mathialagan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 12, 2017
Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting PolypeptidesRhishikesh Thakare, Hongying Gao, Rachel E Kosa, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 8, 2015
Integrated Pharmacokinetic/Pharmacodynamic Analysis for Determining the Minimal Anticipated Biological Effect Level of a Novel Anti-CD28 Receptor Antagonist BMS-931699Zheng Yang, Haiqing Wang, Theodora W Salcedo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|April 19, 2005
Induction of CYP1A in the beagle dog by an inhibitor of kinase insert domain-containing receptor: differential effects in vitro and in vivo on mRNA and functional activityChristopher R Gibson, Charles Lin, Rominder Singh, et al.
Clinical Pharmacology and Therapeutics|August 24, 2018
Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium PerspectiveJ Gerry Kenna, Kunal S Taskar, Christina Battista, et al.
ACS Medicinal Chemistry Letters|December 21, 2016
Discovery of Highly Potent Liver X Receptor β AgonistsEllen K Kick, Brett B Busch, Richard Martin, et al.
Pageof 14